Molecular size (~2.7KDa) and amphipathic character of ReAlta’s peptides enable efficient tissue penetration
Simultaneous and independent inhibition of complement and neutrophil effectors at the most destructive stages of the inflammatory cascade
Small molecular size enables ReAlta’s peptides to cross an intact blood-brain barrier
No off-target effects as ReAlta’s peptides exert their activity extracellularly
Proprietary peptides do not generate anti-drug antibodies
Multiple routes of administration
Pegtarazimod was derived from a mechanistic discovery of the human astrovirus HAstV-1, a virus known to cause non-inflammatory gastroenteritis, which provided a novel scaffold for innate immune modulation. The peptide is uniquely suited for development as a therapy for hypoxic ischemic encephalopathy (HIE) due to its dual-targeting mechanism addressing key drivers of inflammatory brain injury and its ability to cross the blood-brain barrier.
In preclinical models, pegtarazimod has demonstrated a marked reduction in cerebral infarction and meaningful improvements in brain function. Disease-modifying potential is supported by histological findings, neuroimaging (including MRI), and neurocognitive outcome measures, positioning pegtarazimod as a differentiated therapeutic approach in a setting with profound unmet need.
ReAlta is currently enrolling the Phase 2 STAR trial for pegtarazimod in newborns with moderate or severe HIE in neonatal intensive care units across the U.S. More information about the STAR trial is available on clinicaltrials.gov (NCT05778188)
https://clinicaltrials.gov/study/NCT05778188
HIE Phase 2 interim data available for discussion under CDA.
